title: Modification of innervation pattern by fluoroquinolone treatment in the rat salivary glands.
abstract: Fluoroquinolone antibiotics (FQAs) are widely used in dental and medical therapy. Despite their known severe adverse actions on the central and peripheral nervous system, little attention has been directed toward the potential toxic side effects of these compounds on the oral tissues. As the saliva secretion is controlled by the nervous system and neuropeptides, the neurotoxic effect of pefloxacin (PEF), a representative member of FQAs, was studied in rats in the present work. Previously, we demonstrated a significant weight loss of parotid gland tissue, a marked decrease in 3H-thymidine incorporation, a decreased volume of saliva and amylase activity of the glandular tissue in response to PEF. Animals received intraperitoneal injection of PEF (20 mg/100 g body weight daily) for 3 and 7 days. Normal histology, and neurofilament 200, substance P (SP) and calcitonin gene-related polypeptide (CGRP) containing nerve fibers were detected with immunohistochemical methods. A marked decrease of the weights in salivary glands and the acinar diameters were measured. Similarly, a strong and significant decrease of the number of SP and CGRP containing nerve fibers were detected. These findings suggest that the impaired morphology and innervation pattern of salivary glands is related to the neurotoxic adverse effect of FQA treatment.
authors: Department of Restorative Dentistry, University of Debrecen, Medical and Health Science Center, Hungary.
authors: Barna
authors: B
authors: Kelentey
authors: Adam
authors: A
authors: Deak
authors: Tivadar
authors: T
authors: Zelles
authors: Klara
authors: K
authors: Matesz
authors: Istvan
authors: I
authors: Földes
authors: Gabor
authors: G
authors: Veress
authors: Timea
authors: T
authors: Bacskai
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000633:toxicity*; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism; D005260:Female; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D016900:Neurofilament Proteins / Q000378:metabolism; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D009929:Organ Size; D010306:Parotid Gland / Q000294:innervation* / Q000473:pathology; D015366:Pefloxacin / Q000008:administration & dosage / Q000633:toxicity*; D017933:Peripheral Nervous System / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013361:Sublingual Gland / Q000294:innervation* / Q000473:pathology; D013373:Substance P / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D016900:Neurofilament Proteins; C051774:neurofilament protein H; D015366:Pefloxacin; D013373:Substance P; D015740:Calcitonin Gene-Related Peptide